Novartis | NOVN - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
AbbVie USD 9.39B 4.16B 2026-03
Alcon AG USD 1.58B 80M 2026-03
Almirall EUR 337.77M 14.83M 2025-12
Amgen USD 12.04B 2.91B 2026-03
AstraZeneca USD 7.56B 1.85B 2026-03
Autolus Therapeutics Ltd USD 130.92M 26.79M 2026-03
Bayer EUR 6.67B 774M 2025-12
Biogen USD 3.38B 374.2M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Eli Lilly USD 5.28B 1.99B 2026-03
Fresenius EUR 1.31B 81M 2025-12
Fresenius Medical Care EUR 1.24B 343.37M 2026-03
Genmab DKK 1.72B 46M 2025-12
Gilead Sciences USD 7.56B 234M 2025-12
GlaxoSmithKline GBP 3.44B 292M 2026-03
GRIFOLS EUR 801M 242.31M 2025-12
Hikma Pharmaceutical USD 236M 48M 2025-06
J&J USD 21.69B 1.98B 2026-03
Lakefront Biotherapeutics EUR 66.8M 21.06M 2026-03
Lonza CHF 719M 188M 2025-12
Merck EUR 2.33B 77M 2025-12
Merck USD 5.33B 9.24B 2026-03
Novartis USD 6.88B 4.56B 2026-03
Novartis USD 9.56B 2.9B 2025-09
Novo Nordisk A/S DKK 18.44B 5.78B 2025-06
Orion EUR 160.9M 63.3M 2025-12
Pfizer USD 1.7B 561M 2026-03
Philips EUR 2.79B 882M 2025-12
Recordati EUR 428.82M 42.64M 2025-12
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
UCB EUR 1.57B 1.14B 2024-12